Multiple Recurrent De Novo CNVs, Including Duplications of the 7q11.23 Williams Syndrome Region, Are Strongly Associated with Autism  by Sanders, Stephan J. et al.
Neuron
ArticleMultiple Recurrent De Novo CNVs, Including
Duplications of the 7q11.23 Williams Syndrome
Region, Are Strongly Associated with Autism
Stephan J. Sanders,1,2,3,4 A. Gulhan Ercan-Sencicek,1,2,3,4 Vanessa Hus,5,36 Rui Luo,6,36 Michael T. Murtha,1,2,3,4
Daniel Moreno-De-Luca,7 Su H. Chu,8 Michael P. Moreau,9 Abha R. Gupta,2,10 Susanne A. Thomson,11
Christopher E. Mason,12 Kaya Bilguvar,1,4,13 Patricia B.S. Celestino-Soper,14 Murim Choi,4,27 Emily L. Crawford,11
LeaDavis,15 Nicole R. DavisWright,2 RahulM. Dhodapkar,2Michael DiCola,9 NicholasM. DiLullo,2 Thomas V. Fernandez,2
Vikram Fielding-Singh,16 Daniel O. Fishman,17 Stephanie Frahm,9 Rouben Garagaloyan,18 Gerald S. Goh,4
Sindhuja Kammela,2 Lambertus Klei,19 Jennifer K. Lowe,20 Sabata C. Lund,5 Anna D. McGrew,11 Kyle A. Meyer,21
William J.Moffat,2 JohnD.Murdoch,4 Brian J. O’Roak,22 Gordon T. Ober,2 Rebecca S. Pottenger,23Melanie J. Raubeson,2
Youeun Song,2 Qi Wang,9 Brian L. Yaspan,11 Timothy W. Yu,24 Ilana R. Yurkiewicz,2 Arthur L. Beaudet,14
Rita M. Cantor,6,25 Martin Curland,18 Dorothy E. Grice,26 Murat Gu¨nel,1,4,13 Richard P. Lifton,4,27 Shrikant M. Mane,28
Donna M. Martin,29 Chad A. Shaw,14 Michael Sheldon,30 Jay A. Tischfield,30 Christopher A. Walsh,31 Eric M. Morrow,32
David H. Ledbetter,33 Eric Fombonne,34 Catherine Lord,5,35 Christa LeseMartin,7 Andrew I. Brooks,9 James S. Sutcliffe,11
Edwin H. Cook, Jr.,15,36 Daniel Geschwind,20,36 Kathryn Roeder,8 Bernie Devlin,19 and Matthew W. State1,2,3,4,*
1Program on Neurogenetics
2Child Study Center
3Department of Psychiatry
4Department of Genetics
Yale University School of Medicine, 230 South Frontage Road, New Haven, CT 06520, USA
5University of Michigan Autism & Communication Disorders Center, 1111 E. Catherine Street, Ann Arbor, MI 48109-2054, USA
6Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
7Department of Human Genetics, Emory University School of Medicine, 615 Michael Street, Suite 301, Atlanta, GA 30322, USA
8Department of Statistics, Carnegie Mellon University, Pittsburgh, PA 15213, USA
9Bionomics Research & Technology, Environmental andOccupational Health Sciences Institute, Rutgers, The State University of New Jersey,
170 Frelinghuysen Road, Piscataway, NJ 08854, USA
10Department of Pediatrics, Yale University School of Medicine, 230 South Frontage Road, New Haven, CT 06520, USA
11Department of Molecular Physiology & Biophysics, Center for Molecular Neuroscience, Vanderbilt University, 6133 MRB 3, U9220 MRBIII,
Nashville, TN 37232-8548, USA
12Department of Physiology and Biophysics and the Institute for Computational Biomedicine, Weill Cornell Medical College, 1305 York
Avenue, Room Y13-04, PO Box 140, New York, NY 10021, USA
13Departments ofNeurosurgery andNeurobiology, YaleUniversity School ofMedicine, 333CedarStreet, TMP430,NewHaven,CT06510,USA
14Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, T617, Houston, TX 77030, USA
15Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago, 1747 W. Roosevelt Road, Room 155, Chicago,
IL 60608, USA
16Stanford University School of Medicine, Li Ka Shing Building, 291 Campus Drive, Stanford, CA 94305, USA
17Vanderbilt University School of Medicine, 215 Light Hall, Nashville, TN 37232, USA
18Microangelo Associates LLC, 736 Hartzell Street, Pacific Palisades, CA 90272, USA
19Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
20Neurogenetics Program, Department of Neurology and Center for Autism Research and Treatment, Semel Institute, David Geffen School of
Medicine, University of California Los Angeles, 2309 Gonda Building, 695 Charles E. Young Drive South, Los Angeles, CA 90095, USA
21Interdepartmental Neuroscience Program, Yale University, 333 Cedar Street, New Haven, CT 06510, USA
22Department of Genome Sciences, University of Washington, Box 355065, Seattle, WA 98195, USA
23Computer Science, Princeton University, 1264 Frist Campus Center, Princeton, NJ 08544, USA
24Division of Genetics, Children’s Hospital Boston, Harvard Medical School, Department of Neurology, Massachusetts General Hospital,
3 Blackfan Circle, Boston, MA 02115, USA
25Department of Psychiatry, DavidGeffen School of Medicine at UCLA, 695Charles E. YoungDrive South, Los Angeles, CA 90095-7088, USA
26Division of Child and Adolescent Psychiatry, Department of Psychiatry, Columbia University and New York State Psychiatric Institute,
1051 Riverside Drive, Unit 78, New York, NY 10032, USA
27Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06510, USA
28Yale Center for Genome Analysis, 137-141 Frontage Road, Building B-36, Orange, CT 06477, USA
29Departments of Pediatrics and HumanGenetics, 3520AMSRB I, 1150W.Medical Center Drive, The University of MichiganMedical Center,
Ann Arbor, MI 48109-5652, USA
30Department of Genetics and the Human Genetics Institute, Rutgers University, 145 Bevier Road, Room 136, Piscataway, NJ 08854-8082,
USA
31Howard Hughes Medical Institute and Division of Genetics, Children’s Hospital Boston, and Neurology and Pediatrics, Harvard Medical
School Center for Life Sciences, 3 Blackfan Circle, Boston, MA 02115, USA
32Department of Molecular Biology, Cell Biology and Biochemistry and Department of Psychiatry and Human Behavior, Brown University,
70 Ship Street, Box G-E4, Providence, RI 02912, USANeuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc. 863
Neuron
Recurrent De Novo CNVs Show Strong ASD Association33Geisinger Health System, 100 North Academy Avenue, Danville, PA 17822-2201, USA
34Department of Psychiatry, McGill University, Montreal Children’s Hospital, 4018 Sainte-Catherine West, Montreal, Quebec H3Z 1P2,
Canada
35Departments of Psychology, Pediatrics, and Psychiatry and Center for Human Growth and Development, 1111 East Catherine Street,
University of Michigan, Ann Arbor, MI 48109-2054, USA
36These authors contributed equally to this work
*Correspondence: matthew.state@yale.edu
DOI 10.1016/j.neuron.2011.05.002SUMMARY
We have undertaken a genome-wide analysis of rare
copy-number variation (CNV) in 1124 autism spec-
trum disorder (ASD) families, each comprised of
a single proband, unaffected parents, and, in most
kindreds, an unaffected sibling. We find significant
association of ASD with de novo duplications of
7q11.23, where the reciprocal deletion causes
Williams-Beuren syndrome, characterizedbyahighly
social personality. We identify rare recurrent de novo
CNVs at five additional regions, including 16p13.2
(encompassing genes USP7 and C16orf72) and
Cadherin 13, and implement a rigorous approach
to evaluating the statistical significance of these
observations. Overall, large de novo CNVs, particu-
larly those encompassing multiple genes, confer
substantial risks (OR = 5.6; CI = 2.6–12.0, p = 2.4 3
10-7). We estimate there are 130–234 ASD-related
CNV regions in the human genome and present
compelling evidence, based on cumulative data, for
association of rare de novo events at 7q11.23,
15q11.2-13.1, 16p11.2, and Neurexin 1.
INTRODUCTION
Autism spectrum disorders (ASD) are defined by impairments in
reciprocal social interaction, communication, and the presence
of stereotyped repetitive behaviors and/or highly restricted inter-
ests. A genetic contribution is well established from twin studies
(Bailey et al., 1995; Lichtenstein et al., 2010; Liu et al., 2001).
Moreover, the large difference between monozygotic and dizy-
gotic concordance rates is consistent with the contribution of
de novo mutation and/or complex inheritance. In addition, the
overrepresentation of ASD in monogenic developmental disor-
ders (Klauck et al., 1997; Smalley et al., 1992), gene discovery
in families with Mendelian forms of the syndrome (Morrow
et al., 2008; Strauss et al., 2006), and long-standing evidence
for an increased burden of gross chromosomal abnormalities
in affected individuals (Bugge et al., 2000; Veenstra-Vander-
weele et al., 2004; Vorstman et al., 2006; Wassink et al., 2001)
all point to the importance of genetic risks.
Over the last several years, dramatic advances have emerged
from studies of copy-number variation (CNV) characterizing864 Neuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc.submicroscopic chromosomal deletions and duplications (Iaf-
rate et al., 2004; Sebat et al., 2004). Sebat et al. (2007) first noted
that ‘‘large’’ (mean size of 2.3 Mb), rare (<1% frequency in the
general population), de novo events were more frequent in
ASD probands identified in families with only a single affected
child (i.e., simplex families) compared to controls, or versus
probands from families with more than one affected individual
(i.e., multiplex families).
This overrepresentation of large de novo CNVs in ASD has
been replicated in three subsequent studies involving cohorts
ranging in size from 60 to 393 simplex trios (Itsara et al., 2010;
Marshall et al., 2008; Pinto et al., 2010). Two of these studies
(Marshall et al., 2008; Pinto et al., 2010) have also confirmed
an excess in simplex versus multiplex ASD families. Across all
studies, the burden of rare de novo CNVs in simplex probands
(i.e., the percentage of individuals carrying R1 rare de novo
event) has ranged from 5.0% to 11% (Table S1, available online).
Rare structural variants, both transmitted and de novo, have also
shown varying degrees of evidence for association with ASD.
These include deletions and/or duplications at specific loci,
including 1q21.1, 15q11.2-13.1, 15q13.2-13.3, 16p11.2, 17q12,
and 22q11.2, as well as recurrent structural variations involving
one or a small number of genes, including Neurexin 1 (NRXN1),
Contactin 4 (CNTN4), Neuroligin 1 (NLGN1), Astrotactin 2
(ASTN2) and the contiguous genes Patched Domain Containing
1 (PTCHD1) and DEAD box Protein 53 (DDX53) (Bucan et al.,
2009; Glessner et al., 2009; Kumar et al., 2008; Marshall et al.,
2008; Moreno-De-Luca et al., 2010; Noor et al., 2010; Pinto
et al., 2010; Weiss et al., 2008).
To date, the number of definitive replicated findings from these
studies has remained relatively small and all evidence has pointed
to a highly heterogeneous allelic architecture as no risk variant is
present in more than 1% of affected individuals. In addition,
examples of incomplete penetrance (not all mutation carriers
have disease) and affected siblings not sharing the same risk
variant have been the rule rather than the exception. Moreover,
remarkably diverse outcomes have been identified for apparently
identical CNVs. For example, chromosome 16p11.2 deletions or
duplications have been found in individuals with ASD and intellec-
tual disability (ID) (Weiss et al., 2008), seizure disorder (Mefford
et al., 2009), obesity (Bochukova et al., 2010), macrocephaly,
and schizophrenia (McCarthy et al., 2009). These complexities
suggest that the use of association strategies to demonstrate an
excessofspecificdenovoCNVswillplayan important role indefin-
itively implicating loci in ASD.
We have conducted a genome-wide analysis of rare CNVs in
4457 individuals comprising 1174 simplex ASD families from
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Figure 1. Flow Chart of CNV Detection
and Confirmation in the Simons Simplex
Collection
CNV detection was optimized by qPCR analysis of
115 predictions (Table S1 and Figure S1). Quality
control was performed to check for identity error
and data quality (Supplemental Experimental
Procedures). De novo detection was optimized by
qPCR analysis of 403 predictions (Figure S1)
leading to the threshold of R20 probes and
refinement of the prediction algorithm. All de novo
CNVs reported in the study were confirmed by
using qPCR with absolute quantification.
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Recurrent De Novo CNVs Show Strong ASD Associationthe Simons Simplex Collection (SSC) (Fischbach and Lord,
2010). Each family has been extensively phenotyped, with
a single affected offspring, unaffected parents, and, in the
majority of cases, at least one unaffected sibling. This ascer-
tainment strategy was designed to enrich for rare de novo
risk variants. In addition, the family quartet structure allows
for proband versus sibling comparisons that should mitigate
a wide range of technical and methodological confounders
that have plagued association study designs (Altshuler et al.,
2008). We have also developed and apply a rigorous approach
to evaluating the genome-wide significance of recurrent rare de
novo events. Consequently, both the scale and design of this
study provide a valuable opportunity to investigate the contri-
butions of rare de novo and rare transmitted variants in simplex
families, to identify ASD risk loci, to evaluate the relationship
between rare structural variation and social and intellectualNeuron 70, 863–disability (ID), and to place these findings
in the context of previous ASD data,
particularly with regard to rare de novo
CNVs.
RESULTS
Simons Simplex Collection
Summary Characteristics
A total of 4457 individuals from 1174
families were included in the study. Data
from 1124 families passed all quality
control steps; 872 families were quartets
that included two unaffected parents,
a proband, and one unaffected sibling;
252 families were trios that included
two unaffected parents and a proband
(Figure 1).
The male-to-female ratio for probands
was 6.2:1. All had confirmed ASD diag-
noses based on well-accepted research
criteria (Risi et al., 2006), including
autism, 1006 (89.5%), pervasive develop-
mental disorder-not otherwise specified,
96 (8.5%), and Asperger syndrome, 22
(2%). The mean age at inclusion was9.1 years for probands (4–18 years) and 10.0 years (3.5–26 years)
for siblings. The mean (± 95% CI) full-scale IQ in probands was
85.1 ± 1.5; however, the range was considerable (<20–167, Fig-
ure 3): themean verbal IQwas 81.9 ± 1.7 and themean nonverbal
IQ was 88.4 ± 1.4. Self-reported ancestry was as follows: White
non-Hispanic, 74.5%; mixed, 9.3%; Asian, 4.3%; White
Hispanic, 4.0%; African-American, 3.8%; other, 4.2%. Addi-
tional phenotypic data may be found in recent publications
(Fischbach and Lord, 2010) and at www.sfari.org/simons-
simplex-collection.
Illumina 1MArraysAccurately Detect BothRareDeNovo
and Transmitted CNVs
DNA samples derived from whole blood (n = 4381), cell lines
(n = 68), or saliva (n = 8) were genotyped on the Illumina
IMv1 (334 families) or Illumina IMv3 Duo Bead arrays (840885, June 9, 2011 ª2011 Elsevier Inc. 865
Neuron
Recurrent De Novo CNVs Show Strong ASD Associationfamilies), which share 1,040,853 probes in common. CNV
prediction was performed by PennCNV (PN) (Wang et al.,
2007), QuantiSNP (QT) (Colella et al., 2007), and GNOSIS (GN),
(www.CNVision.org) (Figure 1). To assess detection accuracy,
we evaluated 115 predicted rare CNVs (%50% of the span of
the event found at > 1% in the Database of Genomic Variation
[DGV; http://projects.tcag.ca/variation/]) by quantitative poly-
merase chain reaction (qPCR). A higher positive predictive value
was observed for CNVs called by PN and QT, with or without GN
(PPV = 97% with GN, PPV = 83% without) than for other combi-
nations of algorithms, irrespective of the number of probes
mapping within the structural variation (Table S2 and Figure S1);
these ‘‘high-confidence’’ criteria were subsequently used to
identify all rare transmitted CNVs.
Given a particular interest in de novo variation and the relative
challenge of accurately detecting these CNVs (Lupski, 2007), we
sought to optimize our detection strategy further for this class of
structural variation by using the first 585 quartets with complete
genotyping data (Figure 1). We identified de novo events from
among the predicted rare high-confidence CNVs based on the
combination of within-family intensity and genotypic data and
used a blinded qPCR confirmation process (Figure S1). Fifty-
three percent of de novo predictions based on R20 probes
(n = 94) were confirmed compared with 2.6% based on <20
probes (n = 430). Eighty-two percent of failures were false-posi-
tive predictions in offspring; 18% were false-negatives in
parents. The data from this experiment were then used to further
refine de novo prediction thresholds (Supplemental Experi-
mental Procedures). In addition, given the large number of
predictions of small CNVs, and the low yield of true positives in
the pilot data set (Figure S1), we elected to restrict all further
statistical analysis to those rare de novo events that both encom-
passed R20 probes and were confirmed by qPCR in whole-
blood DNA (Figure S1).
Subsequently, at the conclusion of our study, we were able
to evaluate our methods further via a comparison of confirmed
de novo CNVs identified in our study versus those detected by
Nimblegen 2.1M arrays from among a total of 1340 overlap-
ping subjects (probands or siblings), as described by Levy
and colleagues in this issue (Levy et al., 2011). At a threshold
of R20 Illumina probes mapping within a genomic interval
a combined total of 58 rare de novo CNVs were identified
across the two studies, with each array type identifying 95%
(n = 55) of the total. This suggests that the combined results
across the two studies are very likely to represent the com-
plete set of large de novo CNVs present in this SSC sample.
Though not included in our subsequent statistical analysis,
we also compared results for CNVs that mapped to regions
encompassing fewer than 20 probes on the Illumina array.
A total of 31 small rare de novo CNVs were identified
between the two groups with approximately twice as many
found by using the 2.1 M Nimblegen array versus the 1 M Illu-
mina array (23 CNVs versus 12 CNVs, respectively). Of these
31 events, only 13% (n = 4) were identified by both groups,
suggesting that the sensitivity for small de novo events was
low for both arrays and that, as anticipated, there is a pool
of small de novo structural events that were not captured in
our analyses.866 Neuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc.Analysis of Rare De Novo CNVs in the Simons
Simplex Collection
Rare De Novo Genic CNVs Are Overrepresented
in Simplex Probands
In light of strong prior evidence for an increased burden of
de novo CNVS in simplex autism (Itsara et al., 2010; Marshall
et al., 2008; Pinto et al., 2010; Sebat et al., 2007), we investigated
these events in probands versus their unaffected siblings in all
872 quartets included in this study (Figure 1). A total of 28,610
rare, high-confidence CNVs were identified, 97 were classified
as rare and probably de novo, and 83 events were confirmed to
be rare de novo CNVs by qPCR in whole-blood DNA (Table S4).
Rare de novo CNVs were significantly more common among
probands than siblings. Overall, 5.8% of probands (n = 51 of
872) had at least one rare de novo CNV compared with 1.7%
of their unaffected siblings (n = 15 of 872), yielding an odds ratio
(OR) of 3.5 (CI = 2.2–7.5, p = 6.9 3 106, Fisher’s exact test)
(Table 1 and Figure 2). When we considered the proportion of
individuals carrying at least one rare de novo CNV encompass-
ing more than one gene (multigenic CNVs), the OR increased
to 5.6 (43 in probands versus 8 in siblings; CI = 2.6–12.0,
p = 2.4 3 107). These results remained consistent regardless
of whether we analyzed total numbers of CNVs, the proportion
of individuals with at least one rare structural variant (Figure 2),
or increased the stringency of the definition for rarity (Supple-
mental Experimental Procedures).
Given the strong male predominance and increased rates of
ASD in monogenic X-linked intellectual disability syndromes,
we paid particular attention to rare de novo CNVs on the X chro-
mosome but found only two events: one genic deletion present in
a male at the gene DDX53 and a duplication involving six genes
in a female sibling (Xq11.1). This small number precluded mean-
ingful group comparisons. Importantly, no statistical results
reported in this articlewere substantively altered by the exclusion
of 15confirmed raredenovoCNVs identifiedduringour detection
optimization experiments that did not then meet our minimum
probe criteria to be included in our analyses (Table S4). It is of
note, however, that one of these was an exonic deletion of
NLGN3 on chromosome X in a male proband (Table S4).
The burden of rare de novo CNVs in these simplex families is
remarkably similar to previously published results (Table S1)
despite varying CNV discovery approaches and array densities
ranging from 85,000 (Sebat et al., 2007) to 1million probes (Pinto
et al., 2010). We reasoned that this was probably due to the
particular importance of large de novo events, as their detection
would be least sensitive to differences in probe number and
distribution. Indeed, we found that rare de novo CNVs in
probands tended to be larger than in siblings (mean 1.6 Mb
versus 0.7 Mb) (Figure 2 and Figure S2) and to include a greater
number of genes (16-fold increase in probands and a 29-fold
increase considering only deletions).
In fact, we found that de novo CNVs in probands were both
larger and contained a greater number of genes when these
measures were considered independently. We fit a series of
stepwise linear models that increased in complexity from indi-
vidual predictors to an analysis of covariance model, with size
and affected status as predictors, to a three-term model that
included the interaction of size and affected status. We
Table 1. Burden of De Novo CNVs in Probands and Siblings
Category Analysis All Probands (n = 1,124) Matched Probands (n = 872) Matched Siblings (n = 872) Ratio (OR) p Valuea
De Novo CNVs
CNVs 67 54 16
Samplesb 63 51 15
Proportionc 5.6% 5.8% 1.7% 3.4 (3.5) 3 3 106
Genesd 1417 1153 73 15.8
De Novo Deletions
CNVs 35 31 8
Samples 35 31 8
Proportion 3.1% 3.6% 0.9% 3.9 (4.0) 1 3 104
Genes 638 605 21 28.8
De Novo Duplications
CNVs 32 23 8
Samples 29 21 7
Proportion 2.6% 2.4% 0.8% 3.0 (3.0) 0.006
Genes 779 548 52 10.5
De Novo Genic CNVs
CNVs 66 53 13
Samples 62 50 12
Proportion 5.5% 5.7% 1.4% 4.2 (4.4) 4 3 107
Genes 1417 1153 73 15.8
De Novo Exonic CNVs
CNVs 64 52 11
Samples 60 49 10
Proportion 5.3% 5.6% 1.1% 4.9 (5.1) 9 3 108
Genes 1415 1152 71 16.2
De Novo Multigenic CNVs
CNVs 53 44 9
Samples 52 43 8
Proportion 4.6% 4.9% 0.9% 5.4 (5.6) 2 3 107
Genes 1404 1144 69 16.6
De Novo Autosomal CNVs
CNVs 66 53 14
Samples 62 50 14
Proportion 5.5% 5.7% 1.6% 3.6 (3.7) 2 3 106
Genes 1416 1152 67 17.2
De Novo chrX CNVs
CNVs 1 (male deletion) 1 (male deletion) 2 (female duplications)
Samples 1 (male deletion) 1 (male deletion) 1 (female duplication)
Proportion 0.1% 0.1% 0.1% 1.0 (1.0) 0.75
Genes 1 1 6 0.2
Small De Novo CNVs (<100 kb)
CNVs 8 5 3
Samples 8 5 3
Proportion 0.7% 0.6% 0.3% 1.7 (1.7) 0.36
Genes 8 5 7 0.7
Medium De Novo CNVs (100–1000 kb)
CNVs 32 26 9
Samples 30 25 8
(Continued on next page)
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Table 1. Continued
Category Analysis All Probands (n = 1,124) Matched Probands (n = 872) Matched Siblings (n = 872) Ratio (OR) p Valuea
Proportion 2.7% 2.9% 0.9% 3.1 (3.2) 0.002
Genes 469 392 34 11.5
Large De Novo CNVs (R1,000 kb)
CNVs 27 23 4
Samples 26 22 4
Proportion 2.3% 2.5% 0.5% 5.5 (5.6) 2 3 104
Genes 940 756 32 23.6
Single Occurrence De Novo CNVs
CNVs 44 37 14
Samples 40 34 13
Proportion 3.6% 3.9% 1.5% 2.6 (2.7) 0.001
Genes 862 754 54 14.0
Double Occurrence De Novo CNVs
CNVs 8 8 2
Samples 8 8 2
Proportion 0.7% 0.9% 0.2% 4.0 (4.0) 0.05
Genes 89 102 19 5.4
R3 Occurrence De Novo CNVs
CNVs 15 9 0
Samples 15 9 0
Proportion 1.3% 1.0% 0.0% NA (NA) 0.002
Genes 466 297 0 NA
a Fisher’s exact test.
b Four individuals have multiple de novo CNVs.
c Percent of samples withR1 de novo CNV.
dRefSeq genes within the CNV.
Neuron
Recurrent De Novo CNVs Show Strong ASD Associationconfirmed a significant difference between probands and
siblings with regard to the number of genes within CNVs (esti-
mated b = 11.1 more genes in a proband’s de novo CNV, p =
0.025) even after accounting for the strong effect of the size of
the event (estimated b = 6.8 genes per Mb, p = 1.1 3 109) (Fig-
ure 3A). Considering deletions and duplications separately did
not alter these findings. In summary, the burden of rare de
novo CNVs was greater in probands than in siblings with regard
to total number, size, and gene content.
Strong Association of Rare Recurrent De Novo CNVs
Our interest in identifying specific regions of the genome contrib-
uting to ASD led us to investigate next whether multiple overlap-
ping de novo events were present in probands and then to
compare these findings to siblings. In total, 23 probands carried
recurrent de novo CNVs in six distinct regions of the genome.
Each of these intervals contained from 2 to 11 de novo CNVs
in unrelated probands; no de novo CNVs overlapping these
regions were found in siblings. In contrast, only a single recurrent
de novo event was observed in siblings (16p13.11 in two unre-
lated siblings) and one CNV overlapping the region was also
found in a proband (Figure 4).
The six regions found in probands included seven deletions
and four duplications at chromosome 16p11.2, four duplications
at 7q11.23 (the Williams-Beuren syndrome region), and two
CNVs each at 1q21.1 (two duplications), 15q13.2-q13.3 (one868 Neuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc.deletion, one duplication), 16p13.2 (two duplications), and dis-
rupting the gene Cadherin 13 (CDH13) at 16q23.3 (5 Mb deletion
and an overlapping 34 kb exonic deletion).
The presence of multiple regions showing overlapping rare de
novo CNVs restricted to probands, and the absence of similar
findings in their sibling controls, is striking. However, in contrast
to genome-wide association studies (GWAS) of common vari-
ants, there is no widely accepted statistical approach or
threshold to formally evaluate these results. Consequently, we
set out to develop a rigorous method to assess the significance
of de novo events (Experimental Procedures). To do so, we
determined the null expectation for recurrent rare de novo
CNVs based on our data from unaffected siblings and then
used this expectation to evaluate the p value for finding multiple
recurrences in probands.
With this approach, the probability of finding two rare de novo
CNVs at the same position in probands is 0.53. However, the
observations of four recurrent de novo duplications at 7q11.23
(p = 7 3 106) and 11 recurrent de novo CNVs at 16p11.2
(p = 6 3 1023) are highly significant. In addition, we found that
16p11.2 deletions (n = 7, p = 2 3 1014) and duplications
(n = 4, p = 7 3 106) are strongly associated with ASD when
considered independently (Figure S3).
Prior studies have reported a combination of rare transmitted
and de novo CNVs at ASD risk regions. In our data, we observed
A B C
D E
F G
Figure 2. The Burden of Rare DeNovoCNVs
and Genes Mapping within Them in 872
Probands and 872 Matched Siblings
(A) Percent of individuals with R1 rare de novo
CNV in probands versus siblings. Red = deletions;
blue = duplications for (A) to (E).
(B) Total number of rare de novoCNVs in probands
versus siblings (two probands and one sibling
have more than one).
(C) Number of RefSeq genes (Pruitt et al., 2007)
overlapping rare de novo CNVs in probands
versus siblings.
(D) Percent of individuals with R1 rare de novo
CNV as shown in (A) split by sex. Specific
comparisons and associated p values are given.
(E) Number of RefSeq genes overlapping rare de
novo CNVs as shown in (C) split by sex.
(F) The distribution of rare de novo CNVs by size in
probands (green) and siblings (purple). The
dashed vertical line represents the mean plus two
standard deviations of the sibling events.
(G) The distribution of rare de novo CNVs by
number of RefSeq genes.
Statistical significance was calculated by using
Fisher’s exact test (A and D), sign test (B), Wil-
coxon paired test (C), and Wilcoxon test (E).
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probands, overlapped one of the 51 regions in probands con-
taining at least one rare de novo CNV. Conversely, in siblings
we did not observe any cases in which a rare transmitted
CNV, restricted to siblings, overlapped one of the 16 regions
showing de novo events. Interestingly, the eight regions in
probands showing overlapping rare de novo and rare trans-
mitted CNVs include five of the six intervals characterized by
recurrent rare de novo variants, 1q21.1, 15q13.3, 16p13.2,
16p11.2, and 16q23.3 (Figure 4) and three additional genomic
segments with one rare de novo event each: 2p15, 6p11.2,
and 17q12.
While the use of matched sibling controls should have
precluded any confound of population stratification, we explored
whether genotype data from the parents of probands with
16p11.2 or 7q11.23 CNVs suggested unusual ancestral clus-
tering (Crossett et al., 2010; Lee et al., 2009) pointing to a partic-
ular haplotype that might increase the frequency of de novo
events. We found no evidence for this. In addition, given the
very large number of 16p11.2 CNVs in this study and the wide-Neuron 70, 863–spread attention afforded previous find-
ings at this locus, we considered the
possibility of ascertainment bias. A
review of medical histories obtained at
the time of recruitment revealed that
parents had prior knowledge of a
16p11.2 CNV in two instances (one de
novo duplication, one transmitted dele-
tion). With these events removed from
the analysis, association of both deletions
and duplications remained significant
(p = 3 3 1019, all de novo events [n =
10]; p = 2 3 1014, deletions [n = 7]; p = 0.002, duplications
[n = 3]) (Figure S4).
The Distribution of De Novo CNVs in Probands Supports
Marked Locus Heterogeneity
Given the clear risks conferred by large de novo events, we
sought to use this class of variation to determine the total
number of CNV-mediated de novo ASD risk loci present in the
SSC sample. Based on the frequency distribution of 67 de
novo events identified in probands, we estimated a total of 130
regions in this SSC cohort (Experimental Procedures).
We then evaluated the implications of this estimate for
a second phase of genotyping and CNV analysis, which is
currently under way. We used the total predicted number of de
novo ASD loci to guide a simulation experiment (Supplemental
Experimental Procedures) and found that the most likely
outcome of studying a second cohort of similar composition
and size would be further confirmation of the 7q11.23 and
16p11.2 findings and the identification of two to three additional
regions of significant association. These were most likely to885, June 9, 2011 ª2011 Elsevier Inc. 869
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Figure 3. Genotype-Phenotype Analyses of Probands Carrying Rare De Novo CNVs
(A) The number of RefSeq genes within rare de novo CNVs (genes) versus CNV size (size), with probands (red) versus siblings (blue). The slope of the lines shows
the fitted significant (p = 13 109) relationship between genes and size and the difference between the lines shows the fitted difference for probands and siblings
(p = 0.025). On average, probands have more genes within a rare de novo CNV for any given size.
(B) Genes versus size, with sex of subject encoded by color as noted (sex). The slope of the line shows the fitted significant (p = 73 1010) relationship between
genes and size, while the presence of only one line reflects the lack of significant difference by sex (p = 0.20).
(C) ADOS combined severity score (CSS), a measure of autism severity, against genes and by sex. The lack of a line indicates the absence of a significant
relationship.
(D) Full-scale IQ (IQ) against genes and by sex. The slope shows that IQ declines as a function of genes in males (p = 0.02, Wilcoxon test); there is no significant
relationship in females.
(E) Boxplot for IQ by presence (green) or absence (purple) of a detected rare de novo event in the probands. The whiskers show the maximal value within
a 1.5 multiple of the interquartile range of the upper quartile and the minimal value within a 1.5 multiple of the interquartile range of the lower quartile; the notch
shows the 95% confidence intervals of the median.
(F) Distribution of IQ in probands with (green, n = 63) rare de novo CNVs and without (purple, n = 1061).
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de novo events, namely 1q21.1, 15q13.2-13.3, 16p13.2, and the
CDH13 locus.
Genotype-Phenotype Analyses of Probands Carrying
Any Rare De Novo CNV
Given the availability of highly reliable phenotypic data and long-
standing interest in the role of sex in ASD risk and resilience, we
investigated whether males or females carried quantitatively
different types of rare de novo events and what impact rare de
novo CNVs had on intellectual and social functioning.
We found little evidence for larger or more gene-rich de novo
CNVs in males versus females. By fitting a series of stepwise
linear models, we evaluated whether the number of genes within
a de novo CNV tended to differ after accounting for a critical
covariate, CNV size. Neither sex (p = 0.20) nor the interaction
of size and sex (p = 0.06) was a significant predictor of gene870 Neuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc.number. These results should be viewed with some caution,
however, given a trend toward significance and a relatively small
sample size (Figure 3B).
In contrast, we found that male intellectual functioning was
more vulnerable to the effects of rare de novo CNVs. Again, by
using a series of stepwise linear models we evaluated the rela-
tionship between intellectual functioning, sex, and the number
of genes within rare de novo CNVs. For males, there was a signif-
icant relationship between IQ and number of genes (p = 0.02)
with the model predicting a decrease of 0.42 IQ points for
each additional gene. In contrast, for females the estimated
effect was 10-fold less and did not approach significance
(Figure 3D).
To evaluate if low IQ predicted whether a proband carried
a de novo CNV, we fit a logistic regression model with de novo
CNV status for probands as the outcome and full-scale IQ as
the predictor. We found the accuracy of prediction was quite
Figure 4. Confirmed Recurrent Rare De Novo CNVs
(A) All recurrent de novo CNVs identified in 1124 probands and 872 siblings. The gene count is given when >6 RefSeq genes map to an interval; a complete listing
of genes is presented in Table S4. The total number of de novo andmatching inherited CNVs in probands and siblings is shown for deletions (Del) and duplications
(Dup) in parentheses.
(B) LogR data for four de novo duplications and one control with no CNV (CT) in the 7q11.23 interval. RefSeq genes within this region are noted below the
ideogram; the orange bars represent flanking segmental duplications. NCBI 36 (hg18) genomic coordinates are shown with the scale indicated. The LogR for all
probes within the region is shown; LogR values >0.15 are in blue (suggesting a duplication), while LogR values <0.15 are in red (suggesting a deletion). B allele
frequency data are not shown but support the presence of a corresponding CNV. The approximate boundaries of the CNVs are shown by the vertical dashed red
lines and blue arrows.
(C) LogR data for six duplications (four de novo), eight deletions (seven de novo), and one control with no CNV (CT) in the 16p11.2 interval. The ideogram and
intensity plots are as in (B).
(D) Overlapping rare de novo and rare inherited CNVs identified in the 16p13.2 interval. The brackets show the boundaries of RefSeq genes; two genes are in
common between all three duplications: USP7 and C16orf72. The frequency of duplications in the DGV is shown in purple. The majority of the recurrent de novo
region is not present in the DGV.
(E) Overlapping rare de novo and rare inherited CNVs identified in the 16q23.3 interval. A 34 kb deletion overlaps a 5Mb deletion over aCDH13 exon (represented
by ticks on the gene). The frequency of CNVs observed in the DGV is shown at the bottom in purple.
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Table 2. Phenotypic Comparisons between Subjects with 16p11.2 Deletions, 16p11.2 Duplications, and 7q11.23 Duplications and
Matched Probandsa
16p Deletion
(n = 8),
Mean (SD)
Deletion Matches
(n = 40),
Mean (SD)
16p Duplication
(n = 6),
Mean (SD)
Duplication Matches
(n = 30),
Mean (SD)
7q Duplications
(n = 4),
Mean (SD)
Duplication Matches
(n = 20),
Mean (SD)
Primary
CPEA Dx-autism 75% 98% 83% 97% 100% 85%
CPEA Dx-autism spectrum disorder 13% 3% 0% 0% 0% 10%
CPEA Dx-Asperger syndrome 13% 0% 17% 3% 0% 5%
ADOS Combined
Severity Score
6.5 (1.6) 7.0 (1.7) 7.2 (2.1) 7.4 (1.5) 7.0 (2.2) 7.6 (1.6)
Full-Scale IQ 76.9 (17.6) 82.5 (27.8) 75.7 (23.2) 81.0 (26) 84.0 (14.9) 81.3 (30.5)
BMI 23.2 (6.4) 20.9 (5.3) 17.1 (1.4) 19.3 (5.2) 23.1 (5.9) 21.6 (6.4)
Exploratory
ADI-R social interaction total 17.9 (6.7) 21.3 (5.5) 21.8 (3.5) 19.1 (5.6) 20.0 (5.5) 19.9 (7.0)
ADOS social affect total 9.9 (4.0) 9.5 (4.2) 10.8 (5.3) 10.7 (3.2) 11.0 (4.8) 11.7 (3.3)
ADOS social and
communication total
12.4 (3.9) 11.5 (4.2) 14.2 (6.0) 12.7 (3.1) 11.8 (5.7) 13.7 (3.6)
ADI-R RRB total 5.4 (2.6) 6.8 (2.3) 8.5 (1.9) 6.3 (2.1) 7.3 (1.7) 6.3 (2.6)
ADOS RRB Total 2.0 (1.3) 3.7 (1.9) 4.3 (2.6) 3.6 (1.7) 2.0 (1.4) 4.1 (2.0)
ABC total 46.8 (24.3) 42.0 (28.6) 68.7 (21.5) 42.5 (17.9) 66.0 (26.7) 47.2 (21.0)
ABC irritability 14.9 (9.3) 9.6 (9.1) 19.5 (6.4) 10.5 (7.8) 20.0 (13.0) 12.0 (7.6)
ABC hyperactivity 16.5 (9.1) 13.9 (10.3) 26.7 (6.6) 14.0 (7.9) 20.3 (9.7) 18.3 (9.1)
ABC lethargy/social
withdrawal
9.5 (6.6) 10.0 (7.7) 11.5 (8.6) 10.3 (7.2) 13.8 (8.4) 9.8 (6.2)
Age of first concern 2.8 (1.5) 1.7 (0.9) 1.7 (0.9) 2.0 (0.9) 1.8 (1.0) 2.1 (1.3)
ABC, Aberrant Behavior Checklist; BMI, body mass index; Dx, diagnosis; RRB, restricted and repetitive behavior.
a Significance is shown in bold (p% 0.05) and italics (0.05 < p% 0.1).
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carrying a de novo CNV varied 3-fold for those with the lowest
versus the highest IQ, the odds were never large (0.111 at
IQ = 30, 0.063 at IQ = 80, and 0.036 at IQ = 130). This relationship
did not differ significantly by sex (interaction of IQ and sex,
p = 0.12).
Finally, we investigated the relationship between IQ, sex, and
number of genes within rare de novo CNVs to determine whether
any of the models significantly predicted ASD severity
(measured by the ADOS combined severity score [CSS]). Of
these, only full-scale IQ did (p = 0.02).
Overall, the data showed a strong effect of large rare genic de
novo CNVs on the presence or absence of an ASD diagnosis, but
did not support either IQ or ASD severity as useful predictors for
probands carrying these risk variants (Figure 3C). We did
observe a trend towardmore gene-rich de novo CNVs in females
(Figure 2) and found females to be less vulnerable to the reduc-
tion in IQ associated with rare de novo CNVs.
Genotype-Phenotype Analyses of Probands Carrying
16p11.2 and 7q11.23 CNVs
We next investigated whether individuals with recurrent CNVs at
16p11.2 or 7q11.23 showed distinctive behavioral or cognitive
profiles compared with probands who were not carrying rare
de novo events. For each proband carrying a de novo CNV at872 Neuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc.16p11.2 or 7q11.23, five other probands were selected as
controls based on hierarchical matching criteria: first age, then
sex, genetic distance, ascertainment site, and whether the
sample was from a quartet or trio.
Our primary analysis focused on four variables: full-scale IQ,
categorical diagnosis, severity of autism, and body mass index
(BMI) (Table 2), with the latter motivated by multiple reports
that 16p11.2 deletions contribute to obesity (Bijlsma et al.,
2009; Walters et al., 2010). We then pursued a broader explor-
atory study of additional phenotypic variables, ten of which are
presented in Table 2 with the remainder in Table S5.
We found that probands carrying a 16p11.2 or 7q11.23
de novo CNV were indistinguishable from the larger group with
regard to IQ, ASD severity, or categorical autism diagnosis
(Table 2). However, we did find a relationship between body
weight and 16p11.2 deletions and duplications.Whenwe treated
copy number as an ordinal variable (one, two, and three copies)
and used the matched controls as the diploid sample, BMI
diminished as 16p11.2 copy number increased (estimated
b = 3.1kg/m2 for each extra copy, p = 0.02).
The extensive phenotypic data available on the SSC sample
constitute a great resource for fine-grained analyses of geno-
type-phenotype relationships. In the current study, the limiting
factor with regard to recurrent de novo CNVs was the small
sample size, even for 16p11.2 duplications and deletions.
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phenotypic features and found several that yielded significant p
values.While nonewould survive correction for multiple compar-
isons, we report them here in the interest of generating hypoth-
eses for future studies (Table 2 and Table S5). For example, indi-
viduals with 16p11.2 duplications had higher hyperactivity
scores compared to matched control probands, while probands
carrying 7q11.23 duplications showed significantly more behav-
ioral problems (Aberrant Behavior Checklist total), but less
severe social and communication impairment during ADOS
administration.
Analysis of Rare Transmitted CNVs in the SSC
Rare Transmitted Autosomal CNVs Are Equally
Represented in Probands and Siblings
Given the very strong association of rare de novo CNVs, wewere
surprised to find that rare transmitted CNVs were not present in
a greater proportion of probands compared to siblings (Figure 5).
As prior studies have shown an increased burden of specific
subsets of CNVs in neuropsychiatric disorders including autism
and schizophrenia, we consideredmultiple subcategories of rare
transmitted events as well, including genic, exonic, brain-ex-
pressed, and ASD-related, and did not find a statistically signif-
icant result that survived correction for multiple comparisons
(Figure 5).
These findings were inconsistent with a recent rigorous, large-
scale CNV study undertaken by the Autism Genome Project
(AGP) (Pinto et al., 2010). Their sample included both simplex
andmultiplex families and identified a significantly higher burden
of genic and ASD-related CNVs in cases versus unrelated
controls. However, there was no differentiation between trans-
mitted and de novo events in this analysis. We reanalyzed our
data by using the identical criteria detailed in their article and
found nearly identical results (Table S6). However, when we
again restricted our evaluation to only rare transmitted CNVs
by removing all confirmed de novoevents therewasnosignificant
difference remaining between probands and siblings, suggesting
that the excess burden in the SSC sample was entirely driven by
rare de novo events.
We pursued this analysis further because of strong evidence
that specific rare transmitted CNVs carry ASD risks as well as
recent hypotheses regarding the centrality of maternal transmis-
sion of rare CNVs to male probands (Zhao et al., 2007). Conse-
quently, we investigated whether mothers were more likely
than fathers to transmit a rare CNV to an affected offspring.
We also askedwhether there was a greater number of maternally
transmitted CNVs in probands versus their unaffected siblings.
Neither analysis showed a significant result after correction for
multiple comparisons despite considering combinations of the
following variables: deletions, duplications, size, exonic, brain-
expressed, and ASD-related. In addition, based on the possi-
bility that risk might be confined to only the rarest transmitted
events, presumably under the strongest purifying selection, we
evaluated ‘‘singleton’’ CNVs, i.e., those observed in only one
parent and transmitted to only one proband or sibling. In this
case, we found a modest, nonsignificant excess of maternally
transmitted CNVs in probands: 344 maternal autosomal single-
tons were transmitted to probands versus 303 transmissions tosiblings (OR = 1.14; p = 0.059, one-sided; p = 0.12, two-sided).
For fathers, there was no similar trend (OR = 1.03; p = 0.37
one-sided).
Rare Transmitted X-Linked CNVs Are Equally
Represented in Probands and Siblings
We asked similar questions regarding transmission of rare
X-linked CNVs from mothers to male probands and obtained
similar results. In a group of 353 male probands and 353
matched male siblings we found, contrary to expectation, that
more siblings carried maternally transmitted rare X chromo-
some CNVs than probands (14% probands versus 18%
siblings, OR = 0.76; p = 0.11), though this difference was not
significant. The result did not change when we evaluated the
various subcategories of rare X-linked CNVs including exonic,
deletions, duplications, size, brain-expressed, or ASD-
associated.
Rare Transmitted CNVs Show Greater Biological
Coherence in Probands versus Siblings
We next considered whether the absence of association of rare
transmitted CNVs might be a consequence of an inability to
differentiate functional from neutral variants. We looked to
pathway analyses to help address this question, reasoning that
if the specific genic content of CNVs contributed to disease
risk, we would find a greater enrichment of biological pathways
in probands compared to their unaffected siblings.
We used two gene ontology and pathway analysis tools,
MetaCore from GeneGo, Inc. and DAVID (Dennis et al., 2003;
Huang et al., 2009), to analyze 1516 genes within CNVs exclu-
sive to probands and 1357 genes exclusive to siblings. The
total number and size of rare transmitted CNVs used to deter-
mine these gene sets were highly similar in probands and
siblings (Figure 5). GeneGo networks identified 22 pathways
showing significant enrichment in probands versus only four
enriched pathways among siblings. This difference was signifi-
cant based on 100 permutations of the data set (p = 0.04).
DAVID yielded consistent results with 59 pathways enriched
in probands and 19 in siblings (p = 0.01, permutation analysis)
(Figure 6).
For the present study, we elected to restrict our evaluation of
pathways to the general question described here. A manuscript
that is in preparation describes a more extensive analysis,
focusing on both structural and gene expression data from
the SSC.
Transmitted Autosomal and X Chromosome CNVs
Overlap with Previously Reported ASD Loci
We next examined all rare CNVs in the SSC in light of previously
reported findings, comparing our data to the list of ASD regions
included in the recent AGP analysis (Pinto et al., 2010). We also
considered genes implicated by recent common variant studies,
including SEMA5A (Weiss et al., 2009),MACROD2 (Anney et al.,
2010),CDH9 andCDH10 (Wang et al., 2009), theMET oncogene
(Campbell et al., 2006), EN2 (Gharani et al., 2004), as well as
selected schizophrenia loci (International Schizophrenia Consor-
tium, 2008; McCarthy et al., 2009; Millar et al., 2000; Stefansson
et al., 2008; Walsh et al., 2008; Xu et al., 2008) (Table 3). We iden-
tified multiple regions in which rare transmitted and/or rare de
novo events corresponded to previously characterized loci in
both ASD and schizophrenia.Neuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc. 873
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Figure 5. Burden of Rare CNVs in 872 Probands and 872 Matched Siblings
(A) Bar graph showing the log(10) number of genes present in all rare CNVs binned by size (in Mb), with probands shown in green and siblings in purple.
(B) The data from (A) with confirmed de novo events excluded, leaving only CNVs transmitted from a parent to offspring.
(C) Only confirmed de novo events are shown.
(D–F) The ratio (y axis) of number of genes in probands versus siblings for specific size thresholds (x axis). Shown are (D) all rare CNVs (transmitted and de novo);
(E) transmitted events; and (F) de novo events only.
(G–K)Thetotal numberof transmitteddeletions (red)andduplications (blue) forprobandsandsiblings forvaryingcategoriesofCNV (shownabove thegraphs).Definitions
are in Supplemental Experimental Procedures. p values (noted above the bars) are calculated by using the sign test and are not corrected for multiple comparisons.
(L–P) As in (G–K), with number of RefSeq genes within the CNVs (y axis). p values (noted above the bars) are estimated with a two-tailed paired t test and are not
corrected for 3000 comparisons.
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Figure 6. Pathway Analysis of Genes Mapping within Transmitted Rare CNVs
(A) The number of pathways with a corrected p value% 0.05 identified in probands (green) and siblings (purple) by the programs MetaCore (GeneGo networks)
and DAVID (level 4 terms). The input consisted of 1516 RefSeq genes found only in transmitted rare CNVs in probands and the 1357 RefSeq genes found only in
transmitted rare CNVs in siblings; p values are from (B) and (C).
(B) Permutation analysis to assess significance of the difference between probands and siblings. The 2873 genes identified in probands or siblings were divided
randomly between probands and siblings in the same initial proportions. The lists were submitted to GeneGo networks and the difference between the number of
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Table 3. CNVs in Genes and Regions Previously Associated with ASD
Gene/Regiona Location (NCBI 36/hg18)
All (de novo)b Deletions (de novo) Duplications (de novo)
Proband Sibling Proband Sibling Proband Sibling
NRXN1 chr2:50,000,991–51,113,178 3 1 3 1 0 0
CDH10 chr5:24,522,967–24,680,668 0 1 0 1 0 0
MET chr7:116,099,695–116,225,676 1 0 0 0 1 0
VPS13B chr8:100,094,669–100,958,984 1 0 1 0 0 0
CACNA1C chr12:2,032,676–2,677,376 1 1 0 0 1 1
UBE3A chr15:23,133,488–23,235,221 1 (1) 0 0 0 1 (1) 0
NF1 chr17:26,446,120–26,728,821 1 0 1 0 0 0
MACROD2 chr20:13,924,146–15,981,841 0 1 0 1 0 0
TBX1 chr22:18,124,225–18,151,112 1 (1) 0 1 (1) 0 0 0
ADSL chr22:39,072,449–39,092,521 2 (1) 2 (0) 1 (1) 1 (0) 1 (0) 1 (0)
NLGN4X chrX:5,818,082–6,156,706 1 M 0 0 0 1 M 0
DMD chrX:31,047,265–33,267,647 1 F 1 M, 5F 1 F 1 M, 5 F 0 0
NLGN3 chrX:70,281,435–70,307,776 1 M (1 M) 0 1 M (1 M) 0 0 0
ATRX chrX:76,647,011–76,928,375 0 1F 0 0 0 1F
FMR1 chrX:146,801,200–146,840,333 1 F 1F 1F 1F 0 0
RPL10 chrX:153,279,911–153,285,232 1 M 0 0 0 1 M 0
1q21.1 chr1:144,022,893–147,496,468 3 (2) 0 0 0 3 (2) 0
3q29 chr3:197,244,288–198,830,238 1 (1) 0 1 (1) 0 0 0
4p16.3 chr4:1–2,043,468 1 (1) 0 0 0 1 (1) 0
7q11.23 chr7:71,970,679–74,254,837 4 (4) 0 0 0 4 (4) 0
15q11.2-13.1 chr15:20,768,955–26,230,781 1 (1) 0 0 0 1 (1) 0
15q13.2-13.3 chr15:28,698,632–30,234,007 3 (2) 0 2 (1) 0 1 (1) 0
16p13.11 chr16:15,421,876–16,200,195 3 (1) 5 (2) 1 (0) 1 (1) 2 (1) 4 (1)
16p11.2 chr16:29,474,810–30,235,818 14 (11) 0 8 (7) 0 6 (4) 0
17q12 chr17:31,893,783–33,277,865 2 (1) 0 2 (1) 0 0 0
22q11.21 typical chr22:17,412,646–19,797,314 1 (1) 0 1 (1) 0 0 0
22q11.21 distal chr22:22,028,923–23,368,015 1 0 0 0 1 0
a For genes a CNV was included if it overlappedR1 exon; for regions CNVs spanningR50% of the region andR1 exon are included.
bDe novo CNV count is in parentheses; for chromosome X sex is indicated by M for male and F for female.
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Finally, we looked for evidence of association for all CNVs in the
SSC sample, common or rare, transmitted or de novo, evaluating
all high-confidence autosomal CNVs together with all confirmed
de novo CNVs. In this instance, we did not use a frequency cutoff
to define a set of rare transmitted events. A total of 3667 recur-
rent regions were identified; 6 showed relative enrichment in
probands and 5 showed relative enrichment in siblings. No result
reached significance after correction for multiple comparisons
(Table S7 and Figure 7C). The region showing the greatest differ-
ence in probands compared to siblings was 16p11.2 (p = 0.001).pathways in probands and siblings was recorded. This process was performed
showed a differenceR18 (the difference seen in [A], vertical dashed line), yieldin
(C) Permutation analysis to calculate the significance value with DAVID (level 4 term
seen in (A), vertical dashed line), giving a p value of 0.01.
(D) All pathways with a corrected p value% 0.05 identified by GeneGo networks
significance value on a logarithmic scale.
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Multiple ASD Samples
An Analysis of De Novo CNVs in 3816 Probands
from Genome-wide Studies of Idiopathic ASD
Supports Association of Six Genomic Intervals
Our approach to assessing the genome-wide significance of rare
recurrent de novo events provides for a statistical evaluation of
CNVs observed in cases without requiring additional matched
control samples. Consequently, we were able to conduct
a cumulative analysis across multiple studies in search of addi-
tional associated ASD loci. We included four other large-scale
ASD CNV studies (Itsara et al., 2010; Marshall et al., 2008; Pinto100 times and the image shows the frequency of the results. Only four events
g a p value of 0.04.
s) by using the samemethods as in (B). A single result wasR40 (the difference
for probands (green) and siblings (purple). The length of the bar represents the
Figure 7. De Novo and Transmitted CNVs in 15q11.2-13
A 13Mb region is identified by the red box on the ideogram at the top.
(Region overview) The RefSeq genes present within the interval andmultiple segmental duplications are identified (the colors identify regions of homology; Makoff
and Flomen, 2007). Five of these segmental duplications are commonly referred to as BP1-BP5.
(Known CNVs) Duplications (blue) and deletions (red) identified that have been reported in the literature; the alternating red and blue colors denote both deletions
and duplications.
(Disease associations) Regions with reported associations to four developmental and neuropsychiatric conditions (Supplemental Experimental Procedures) are
identified. Of note, BP2-BP3 deletions lead to Prader-Willi or Angelman syndromes.
(Transmitted and de novo CNVs) The frequency of duplications (blue) and deletions (red) in the DGV and SSC populations is indicated. While CNVs overlying the
segmental duplications are common, CNVs between the breakpoints are generally rare.
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Recurrent De Novo CNVs Show Strong ASD Associationet al., 2010; Sebat et al., 2007)meeting four criteria: standardized
diagnosis, genome-wide detection, confirmed de novo struc-
tural variations, and sufficient information to permit the identifi-
cation of duplicate samples.
These data sets cataloged 219 confirmed rare de novo CNVs
from a total of 3816 individuals (Table S1). We found six regions
that exceeded the threshold for significance (Experimental
Procedures). Given prior evidence and our own data suggesting
that reciprocal deletions and duplications at the same locus may
both contribute to the ASD phenotype, we evaluated signifi-
cance for combined events at every interval and calculated prob-
abilities for deletions and duplications separately (Table 4 and
Figure S3).
The most frequent recurrent de novo CNV identified across all
studies was 16p11.2 with 19 identified probands (14 deletions,
5 duplications) showing extremely strong evidence for associa-
tion with ASD (23 1055 combined, 53 1029 for deletions, and
2 3 105 for duplications). The proximal long arm of chromo-
some 15 showed two contiguous intervals; the first corresponds
to the region 15q11.2-13.1 or BP2-BP3 (seven duplications, 43
109) (Figure 7A), long cited as the most common cytogenetic
abnormality identified in idiopathic ASD (Cook et al., 1997). We
also found evidence of association for the interval mapping to
15q13.2-13.3 or BP4-BP5 (five duplications and one deletion;
1 3 104 combined, 2 3 105 for duplications) (Figure 7B).
Rare deletions and duplications in this region have previously
been associated with intellectual disability and ASD and dele-
tions have been associated with schizophrenia and epilepsy
(Figure 7). It is important to note, however, that considering
only events restricted to 15q13.2-13.3 (i.e., removing three over-
lapping isodicentric chromosome 15 events) resulted in a loss of
statistical significance (0.53 combined, 0.88 for duplications).
This suggests either that the result is an incidental finding
because of the proximity to a true ASD risk locus or, alterna-
tively, that the smaller 15q13.2-13.3 CNVs might point to a
minimum region of overlap mapping to one or more ASD-related
genes.
Recurrent de novo CNVs exceeding the significance threshold
in the combined sample were also present at 7q11.23 (four dupli-
cations, 0.003), in the 22q11.2 region (three deletions and two
duplications, 0.002 combined; 0.11 for deletions; 0.88 for dupli-
cations), and at the locus coding for the gene NRXN1. For
NRXN1 there were five de novo events: one intronic deletion,
three exonic deletions, and one exonic duplication (0.002
combined, 0.004 for deletions).
Finally, we used the observed number and distribution of de
novo CNVs in the combined proband data set to estimate the
likely number of CNV regions contributing to ASD. From the total
of 219 confirmed de novo events, we derived an estimate of 234(De novo CNVs) Confirmed de novo CNVs in single individuals identified in this st
Pinto et al., 2010; Sebat et al., 2007).
(A) An enlargement of BP2-3 showing the relationship of de novo CNVs, genes, an
MAGEL2, MKRN3, and NDN (Itsara et al., 2010).
(B) An enlargement of BP4-BP5 showing similar data and methods as in (A). Rem
p value (p = 0.62).
(C) An enlargement of the CHRNA7 region showing enrichment of duplications in
test), uncorrected for 3,667 comparisons; the rate of duplications in the DGV is s
878 Neuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc.distinct genomic regions contributing to large ASD-related de
novo structural variations (Experimental Procedures).
DISCUSSION
Our results highlight the importance of rare CNVs for simplex
ASD. We confirm an overrepresentation of rare de novo events
in probands versus siblings with an odds ratio of 3.5 for all vari-
ants, 4.0 for rare de novo genic variants, and 5.6 for de novo
CNVs encompassing more than one gene. We find very strong
evidence for the association of duplications at 7q11.23 by using
a rigorous method for assessing genome-wide significance.
Moreover, we identify four additional rare recurrent de novo
events found only in probands. Two of these, at 1q21 and
15q13.2-13.3, have been previously implicated in neurodevelop-
mental disorders, including ASD, while, to our knowledge those
at 16p13.2 (USP7 and C16orf72) and the CDH13 locus have not.
Each of these four regions also contain rare transmitted CNVs
that are restricted to probands. Finally, we find compelling
evidence confirming the association of both 16p11.2 duplica-
tions and deletions.
It is striking that while we replicate findings of elevated rates
of rare de novo CNVs in simplex families (5.8% of probands
versus 1.7% in siblings), the percentage of the cohort carrying
these events is the same magnitude as that seen previously.
This is despite an intensive focus on the ascertainment of
simplex quartets and a 10-fold increase in probe density since
the earliest CNV studies of ASD. We believe these results are
best explained by the particular contribution of large genic de
novo variants based on our analysis of gene number, CNV
size, and affected status (Figure 3) and by the observation of
consistent results across studies despite steadily increasing
detection resolution.
While it may not seem surprising that large de novo events
carry the greatest risk for developmental disorders, it is inter-
esting to note that we do not find evidence that ASD diagnosis
or severity is mediated by intellectual disability (ID). It has been
argued that ASD in the presence of IDmay reflect an epiphenom-
enon, in which a nonspecific impairment of brain functioning
unmasks and/or exacerbates limitations in an individual’s
capacity for social reciprocity (Skuse, 2007). It has also been
widely held that the detection of large de novo CNVs will be
enhanced by the ascertainment of ASD samples with greater
intellectual disability. Our data show that large de novo CNVs
confer substantial risk for ASD in the SSC, but they are only
modestly correlated with lower IQ and largely independent of
ASD severity.
These data suggest that our study has identified bona fide
high-risk variants for autism spectrum disorders. They also pointudy and prior ASD studies are shown (Itsara et al., 2010; Marshall et al., 2008;
d common regions in the DGV. A small atypical duplication includes the genes
oving the three Class 5A isodicentric chr15 events results in a nonsignificant
probands (n = 10) versus siblings (n = 3). The p value is p = 0.05 (Fisher’s exact
imilar to that seen in probands (Table S7).
Table 4. Two or More Recurrent De Novo Regions across This and Other Studies
Type Band Location (NCBI 36/hg18) Size (kb)
Recurrence
(del/dup)
Frequency
(n = 3,816)
p value
(C = 232)a Studiesb Genesc (RefSeq)
Deletions
2p16.3 chr2:51,002,576–51,157,742 155 2 0.05% 0.94 3 NRXNd
2q24.2 chr2:162,212,720–162,311,972 99 2 0.05% 0.94 5 SLC4A10 (intronic)
2q37.3 chr2: 238,217,066–242,701,103 4,484 2 0.05% 0.94 5 41
3p14.1 chr3:65,674,445–65,725,692 51 2 0.05% 0.94 2,4 MAGI1 (intronic)
3p14.1 chr3:67,223,272–70,633,200 3,410 2 0.05% 0.94 1,4 10
5p15.2 chr5:11,403,359–11,491,117 87 3 0.08% 0.11 1,4 CTNND2
7q31.1-31.31 chr7:113,335,000–119,223,887 5,889 2 0.05% 0.94 4 20
7q36.2 chr7:153,380,710–154,316,928 936 2 0.05% 0.94 3,4 DPP6
9p24.3 chr9:98,998–334,508 235 2 0.05% 0.94 3 C9orf66,CBWD1,
DOCK8,FOXD4
11q13.3 chr11:70,154,458–70,187,872 33 2 0.05% 0.94 3 SHANK2
14q32.12 chr14:92,476,815–92,496,373 19 2 0.05% 0.94 2 ITPK1
15q23-24.1 chr15:69,601,300–71,944,199 2,343 2 0.05% 0.94 1,4 22
16p11.2 chr16:29,578,715–30,001,681 422 14 0.37% 5 3 10–29 1,2,3,4,5 26
16q23.3 chr16:81,796,275–81,830,296 34 2 0.05% 0.94 1 CDH13
16q23.3 chr16:82,557,318–82,683,859 126 2 0.05% 0.94 1,2 MBTPS1,NECAB2, OSGIN1,
SLC38A8
18q22.1 chr18:64,812,093–6,484,6196 34 2 0.05% 0.94 2,4 CCDC102B
20p12.1 chr20:14,616,243–14,751,454 135 2 0.05% 0.94 1,3 MACROD2 (intronic)
22q11.21 chr22:17,257,787–19,786,200 2,528 3 0.08% 0.11 1,3,4 56
22q13.33 chr22:49,243,247–49,465,883 222 3 0.08% 0.11 4,5 16
Duplications
1q21.1 chr1:144,838,175–146,324,832 1,487 2 0.05% 0.88 1 14
2p25.3 chr2:143,279–196,704 53 2 0.05% 0.88 2 0
3q21.2 chr3:125,966,642–127,254,388 1,288 2 0.05% 0.88 2 11
7q11.23 chr7:72,411,506–73,782,113 1,371 4 0.09% 0.003 1 22
8p23.3 chr8:710,491–1,501,580 791 2 0.05% 0.88 3,4 DLGAP2
10q11.23-21.1 chr10:52,699,516–54,408,816 1,709 2 0.05% 0.88 1,2,5 CSTF2T,DKK1, MBL2,PRKG1
12q24.31 chr12:120,628,928–120,862,589 233 2 0.05% 0.88 2,4 7
15q11.2 chr15:21,343,866–21,505,342 161 7 0.18% 4 3 10–9 1,2,3,4,5 MAGEL2,MKRN3,NDN
15q11.2-13.1 chr15:21,240,037–26,095,621 4,856 6 0.16% 4 3 10–4 1,2,3,4,5 12
15q13.2-13.3 chr15:28,723,577–30,231,488 1,508 5e 0.13% 2 3 10–5 1,2,4,5 CHRNA7,KLF13,MTMR10,
MTMR15,OTUD7A,TRPM1
16p13.2 chr16:8,828,382–9,147,487 319 2 0.05% 0.88 1 PMM2,CARHSP1,
USP7,C16orf72
16p11.2 chr16:29,563,365–30,085,308 521 5 0.13% 2 3 10–5 1,3,4 26
20q13.33 chr20:60,949,339–61,220,552 271 2 0.05% 0.88 2,4 7
Combinedf
22q11.21 chr22:17,265,500–19,791,274 2,526 2 0.05% 0.88 2,4 56
1q21.1 chr1:145,013,719–146,293,282 1,280 3 (1/2) 0.08% 0.53 1,2 14
2p16.3 chr2:50,539,877–50,677,835 138 2 (1/1) 0.05% 1.00 3 NRXNd
7q31.1 chr7:108,242,570–108,393,666 151 2 (1/1) 0.05% 1.00 2,4 C7orf66
7q31.1 chr7:111,065,681–111,454,179 388 2 (1/1) 0.05% 1.00 2,4 DOCK4
9p24.3 chr9:175,632–334,508 159 3 (2/1) 0.08% 0.53 1,3 C9orf66,DOCK8
15q13.2-13.3 chr15:28,723,577–30,231,488 1,508 6 (1/5)e 0.16% 1 3 10–4 1,2,4,5 CHRNA7,KLF13,MTMR10,
MTMR15,OTUD7A,TRPM1
16p11.2 chr16:29,578,715–30,001,681 521 19 (14/5) 0.50% 2 3 10–55 1,2,3,4,5 26
(Continued on next page)
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Table 4. Continued
Type Band Location (NCBI 36/hg18) Size (kb)
Recurrence
(del/dup)
Frequency
(n = 3,816)
p value
(C = 232)a Studiesb Genesc (RefSeq)
16q22.3 chr16:69,987,425–70,647,241 660 2 (1/1) 0.05% 1.00 1,2 13
20q13.33 chr20:61,056,624–61,076,763 20 3 (1/2) 0.08% 0.53 2,4 SLC17A9
22q11.21 chr22:17,265,500–19,786,200 2,521 5 (3/2) 0.13% 0.002 1,2,3,4 56
a p values are calculated as described in the Experimental Procedures; values less than p = 0.05 are shown in bold.
b 1 = this study; 2 = Itsara et al., 2010; 3 = Pinto et al., 2010; 4 = Marshall et al., 2008; 5 = Sebat et al., 2007.
c Counts are given for CNVswith >6 RefSeq genesmapping to the interval. A complete listing of genes is in Table S4. All genes shown represent exonic
overlap unless otherwise indicated.
dWhile only two de novo CNVs overlap within NRXN1, there are five de novo events overlapping a section of the gene: one intronic deletion, three
exonic deletions, and one exonic duplication (p = 0.004 combined, p = 0.007 for deletions).
e Three of the duplications contributing to 15q13.2-13.3 are isodicentric chr15 events; because there is a long-standing association with ASD and iso-
dicentric chr15, this region is also considered without these events. For interstitial CNVs alone there are two duplications and one deletion (p = 0.62
combined; p = 0.92 duplications) (Figure 7).
f Regions are only listed in the combined category if there is a combination of deletions and duplications resulting in a different p value when the two
types of CNVs are considered together.
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than has often been supposed: for example, the relatively high
rates of 16p11.2 and 7q11.23 CNVs and low rates of 15q11.2-
13.1 duplications seen in this study compared to others may
reflect the presence of particular subpopulations of rare risk
CNVs that are, in fact, more readily ascertained in cohorts with
higher mean IQ.
The results further show that the risk associated with large
de novo events is related to their greater genic content, even
after controlling for larger size. This observation is consistent
with two countervailing hypotheses: first, that the greater gene
number is a surrogate for the increased chance of disrupting
one particular gene or regulatory region because of the involve-
ment of a larger segment of the genome; or second, that it is the
contribution of multiple genes and/or regulatory regions simulta-
neously within these CNVs that increases risk.
Our data do not allow us to resolve this issue. We suspect that
if many deletions or duplications encompassing small numbers
of genes were as highly penetrant as multigenic events, we
would have begun to show more evidence for this either in the
form of an overall increased burden for smaller de novo varia-
tions and/or an association of specific de novo events. However,
it is important to note that despite having higher resolution than
some prior studies, we still have a clear ascertainment bias for
larger CNVs. It is likely that a combination of high-throughput
sequencing, larger patient cohorts, and increasingly sophisti-
cated approaches to evaluating combinations of risk variants
will begin to shed light on this issue for both sequence and struc-
tural variation.
Our findings with regard to recurrent de novo events in the
SSC sample identify six putative ASD loci and two of these,
7q11.23 and 16p11.2, show clear evidence for genome-wide
association. Moreover, our simulation analysis suggests that
the most likely outcome of the ongoing phase 2 SSC study will
be the confirmation of two to three of the remaining four inter-
vals, namely 1q21.1, 15q13.2-13.3, 16p13.2, and 16q23.3
(CDH13).
The association of recurrent duplications at 7q11.23 points to
particularly promising opportunities to illuminate the molecular
mechanisms of social development. Duplications in this interval880 Neuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc.have previously been described in developmental disorders,
including ASD (Berg et al., 2007; Van der Aa et al., 2009), though
these have been restricted to case reports or series, with
the attendant difficulties in controlling for ascertainment bias.
The identification of clear association of duplications in this
controlled study of ASD is striking, given that the reciprocal
deletion results in a developmental syndrome characterized in
part by an empathic, gregarious, and highly social personality
(Pober, 2010). Moreover, several lines of evidence, including
atypical deletions (Antonell et al., 2010), mousemodels (Fujiwara
et al., 2006; Hoogenraad et al., 2002; Meng et al., 2002;
Sakurai et al., 2011), and gene expression X phenotype studies
(Gao et al., 2010; Korenberg et al., 2000) have already identified
CAP-GLY domain containing linker protein 2 (CLIP2), LIM
domain kinase 1 (LIMK1), General transcription factor II,
i (GTF2i), and Syntaxin 1A (STX1A) as the leading candidates
among the 22 genes within the region for involvement in the
cognitive and social phenotypes. The characterization of this
single interval in which opposite changes in copy number con-
tribute to contrasting social phenotypes promises to set the
stage for a range of intiguing studies of the role gene dosage in
this region plays in the genesis and maintenance of social
behavior.
The strong replication of findings at 16p11.2 likewise high-
lights emerging opportunities for translational neuroscience.
First, the region is sufficiently circumscribed to investigate by
using molecular biological and model systems approaches.
Second, though we cannot quantify an odds ratio from our
data, given the absence of events in siblings, there is clear
evidence from this and prior studies (McCarthy et al., 2009)
that 16p11.2 CNVs carry much larger effects than common vari-
ants contributing to complex common disorders. Third, the 1%
allele frequency observed in ASD cohorts promises an ascer-
tainable cohort of sufficient size to support prospective studies
of natural history, neuroimaging, and treatment response as, for
example, in the recently launched Simons Variation in Individ-
uals Project (https://sfari.org/simons-vip). Given the reported
associations of widely varying outcomes for individuals with
either deletions or duplications at 16p11.2, these studies offer
an important avenue to address the means by which a single
Neuron
Recurrent De Novo CNVs Show Strong ASD Associationlocus may lead to a wide range of psychiatric and develop-
mental outcomes that have previously been conceptualized as
distinct.
Multiple lines of evidence suggest that four other recurrent de
novo CNVs (1q21.1, 15q13.2-13.3, 16p13.2, and 16q23.3) as
well as three intervals in which a single de novo event overlaps
with rare transmitted CNVs (2p15, 6p11.2, and 17q12) are likely
to be true positives. For example, the 2p15 and 17q12 regions
have already been implicated in ASD (Liang et al., 2009;
Moreno-De-Luca et al., 2010). Similarly, rare 1q21.1 and
15q13.2-13.3 CNVs have been identified in developmental and
neuropsychiatric syndromes, with deletions found in ASD (Miller
et al., 2009; Shen et al., 2010), schizophrenia (International
Schizophrenia Consortium, 2008; Stefansson et al., 2008), and
idiopathic epilepsy (Helbig et al., 2009), and recurrent duplica-
tions reported here. To our knowledge, CDH13 (16q23.3) has
not previously been noted to be an ASD risk variant, however
the protein family has been implicated in pathogenesis through
CNV studies (Glessner et al., 2009), homozygosity mapping
(Morrow et al., 2008), and common variant findings (Wang
et al., 2009). The 16p13.2 region contains four genes, the most
notable of which are C16orf72, coding for a protein of unknown
function, recently identified in a schizophrenia CNV study (Levin-
son et al., 2011), and Ubiquitin Specific Peptidase 7 (USP7),
which has been shown to have a role in oxidative stress
response, histone modification, and regulation of chromatin re-
modeling (Khoronenkova et al., 2011). Neither gene has been
specifically highlighted with regard to ASD, however CNVs
involving genes in the ubiquitin pathway have been previously
associated with risk (Glessner et al., 2009).
It is somewhat surprising that the family-based design em-
ployed here played a central role in the identification and con-
firmation of rare variant association. The prevailing practice in
genome-wide association studies of common variants has
been to rely on unrelated case-control designs, given the rela-
tive ease of generating very large samples. It is notable that
the statistical power afforded by the low probability of
observing multiple recurrent rare de novo events by chance
more than compensated for the relatively small cohort (com-
pared to those found in contemporary GWAS). The results at
16p11.2 are a striking example: based on a standard case-
control comparison, the most statistically significant finding
involved 14 events in probands and 0 in siblings (p = 0.001,
Fisher’s exact test) and did not provide evidence sufficient to
withstand correction for multiple comparisons. However, the
analysis of recurrent de novo events convincingly established
association surpassing a genome-wide significance threshold
(p = 6 x 10-23).
It is certain that the SSC sample-ascertainment process
enhanced certain findings and attenuated others. Restricting
the comparison group to siblings limited power to identify asso-
ciation of specific rare recurrent transmitted events; our assess-
ment of significance for de novo CNVs was based on conserva-
tive assumptions and may have excluded true risk loci; the
filtering for rare de novo CNVs and the small sample size cur-
tailed the assessment of multihit hypotheses; the generally older
parental age may have obscured the relationship between age
and de novo variation (Figure S3); and, as noted, limited detec-tion accuracy below 20 probes hindered the assessment of small
de novo structural variations.
However, despite these limitations, the manner in which the
design mitigated important confounds and preserved sufficient
power to detect association of recurrent de novo events yielded
clear benefits, unambiguously replicating prior findings and
identifying additional risk loci. Moreover, this report considers
less than half of the SSC: phase 2 of this study is under way,
as is high-throughput sequencing of the collection, also focusing
on de novo events. Together these endeavors promise to further
illuminate the genomic architecture of simplex autism and to
provide additional critical points of traction in elaborating the
molecular mechanisms and developmental neurobiology under-
lying ASD.
EXPERIMENTAL PROCEDURES
Genotyping
All members of each family were analyzed on the same array version: either
the Illumina IMv1 (334 families) or Illumina IMv3 Duo (840 families) Bead
array. These share 1,040,853 probes in common (representing 97% of
probes on the IMv1 and 87% of probes on the IMv3). Of the 872 quartet
families, 824 (94.5%) had all members hybridized and scanned simulta-
neously on the Illumina iScan in an effort to minimize batch effects and
technical variation.
Identity Quality Control
Genotyped samples were analyzed by using PLINK (Purcell et al., 2007) to
identify incorrect sex, Mendelian inconsistencies, and cryptic relatedness by
assessing inheritance by descent; 11 families were removed as a result.
CNV Detection
CNV detection was performed by using three algorithms: (1) PennCNV
Revision 220, (2) QuantiSNP v1.1, and (3) GNOSIS. PennCNV and Quan-
tiSNP are based on the hidden Markov model. GNOSIS uses a continuous
distribution function to fit the intensity values from the HapMap data and
determine thresholds for significant points in the tails of the distribution
that are used to detect copy-number changes. Analysis and merging of
CNV predictions was performed with CNVision (www.CNVision.org), an in-
house script.
CNV Quality Control
Specific genotyping and CNV parameters are detailed in the Supplemental
Experimental Procedures. Five percent of the samples failed and were rerun;
39 families were removed because of repeated failures.
Criteria for Rare CNVs
A CNV was classified as rare if%50% of its length overlapped regions present
at >1% frequency in the DGV of March 2010.
CNV Burden
Burden analyses were performed on the matched set of 872 probands
and siblings. Typically, three outcomes were assessed: proportion of individ-
uals with R1 CNV matching the criteria (p value calculated with Fisher’s
exact test); number of CNVs matching the criteria (p value calculated
with sign test); and number of RefSeq genes within or overlapping CNVs
matching the criteria (p value calculated with Wilcoxon paired test). Where
burden was assessed for unequal numbers of probands and siblings (e.g.,
by sex) the sign test and Wilcoxon paired test were replaced with the
Wilcoxon test.
Statistical Analysis of De Novo Recurrence
To determine the probability of finding multiple rare de novo CNVs at the
same location in probands, we first estimated how many likely positions inNeuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc. 881
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there are widely varying mutation rates for structural variation across the
genome (Fu et al., 2010), some positions are more likely to result in de
novo CNVs observed in our sample than others. Consequently, the likely
number of positions is much smaller than the total possible number of posi-
tions. We refer to the likely CNV regions as effective copy-number-variable
regions (eCNVRs) and calculate their quantity ‘‘C’’ using the so-called
‘‘unseen species problem,’’ which uses the frequency and number of
observed CNV types (or species) to infer how many species are present in
the population. Based on the observed de novo CNVs in the control sibling
group, we apply the formula C = c/u + g2 d (1  u)/u, in which c = the total
number of distinct species observed; c1 = the number of singleton species;
d = total number of CNVs observed; g = the coefficient of variation of the
fractions of CNVs of each type, and u = 1 – c1/d (Bunge and Fitzpatrick,
1993). (In this calculation, due to the small number of observations, we
assume that g equals 1.) For the de novo events in siblings, c1 = 14, c =
15, d = 16, and C = 232. This calculation is performed in the siblings
because the observed rare de novo CNVs in this group are assumed to
be predominantly nonrisk variants and consequently represent the null
distribution.
Next, we calculate the chance that two de novo eventsmatch at any one of C
eCNVRs in probands by using methods from the classic ‘‘birthday problem’’
which assesses the likelihood of seeing at least one pair of matching birthdays
among a given number of people. Our interest was in seeing >2 matches (m) in
probands under the null hypothesis of no association with ASD. This calcula-
tion is performed empirically by distributing d events at random among C
eCNVRs and then counting the maximum number of CNVs falling in the
same location. Repeating this experiment one million times, we obtained an
estimate of the probability of finding Rm counts for R1 eCNVR under the
null hypothesis.
Given the importance of the estimate of eCNVRs in unaffected populations
for the determination of significance, we recalculated C based on a combined
set of confirmed de novo CNVs in controls described in the literature and
obtained a highly similar result (C = 242) (Supplemental Experimental Proce-
dures). Moreover, we determined that the results reported here remain signif-
icant under the plausible range of estimates for C (Supplemental Experimental
Procedures).
Estimate of Number of De Novo CNV Regions Contributing to ASD
Risk
The unseen species problem was used to predict the total number of ASD risk
loci based on the distribution of de novo CNVs in probands. This required
identification of the de novo CNVs that confer risk; to identify such
CNVs we estimated that 76% of de novo CNVs in probands confer risk
(67 de novo CNVs in probands  16 de novo CNVs expected in siblings/67
de novo CNVs in probands) and assumed that recurrent de novo CNVs
were most likely to be associated with risk and should be included within
this 76%. The remainder of the 76% is made up of 27 single occurrence
de novo CNVs (though we do not identify which ones), leading to an estimate
of the total number of risk-conferring loci as 130 (c1 = 27, c = 33, d = 51).
A similar approach was applied to all de novo CNVs in 3816 probands (count
derived from the literature), leading to an estimate of 234 risk-conferring loci
(c1 = 59, c = 88, d = 158).
Stepwise Assessment of Multiple Variables
Predictors were examined in a logical order, e.g., to evaluate the relationship
between gene number (G), CNV size (L), and affection status (A, proband
versus sibling), we fit a series of increasingly complex linear models in the
following steps: (1) regress response G on predictor L, regress G on A; 2)
if R1 term was significant, and assuming L had the best predictive power,
we regressed G on L and A; (3) assuming L and A were significant jointly,
we regressed G on L, A and L interacting with A. The latter term permits the
slope of the relationship between G and L to differ for probands versus
siblings. In each step, we determined whether the newest term was signifi-
cant, given the terms already in the model. We also fit the model by using
backward elimination, starting with the full model and simplifying it one term
at a time.882 Neuron 70, 863–885, June 9, 2011 ª2011 Elsevier Inc.Population Structure of Recurrent De Novo CNVs
All parents were projected onto a five-dimensional ancestry map by using
eigenvector decomposition (Crossett et al., 2010; Lee et al., 2009). Euclidean
distances were measured for the parents of origin. The mean and median
distances between these pairs of parents were calculated and were evaluated
relative to the remainder of the sample by using a bootstrap procedure
(Supplemental Experimental Procedures).Genotype-Phenotype Analysis
For each sample with a 16p11.2 deletion (eight samples) or duplication
(six samples) or 7q11.23 duplication (four samples), five control probands
were selected based on a matching hierarchy: age (100% of control probands
matched), sex (100%), genetic distance (91%, based on five-dimensional
ancestry map), collecting site (46%), and quartet or trio family (34%).
Probands with de novo CNVs or CNVs in regions previously associated with
ASDwere removed prior to matching; each control proband was only included
once.
For continuous variables each stratum of a ‘‘case’’ proband matched to five
‘‘control’’ probands was treated as a block and the data were analyzed as
a randomized block design by using analysis of covariance. Thus mean values
were allowed to vary across blocks and to be altered by case-control status.
The difference because of the presence of the CNV of interest was assessed
with an F-test with n,M degrees of freedom (n is the number of CNVs of interest
and M is the residual degrees of freedom after accounting for model terms).
Because IQ is known to affect many behavioral measures associated with
ASD, it was treated as a covariate in models for outcomes besides itself and
BMI. For diagnostic status, matching was taken into account by using a condi-
tional logit model.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, nine tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.neuron.2011.05.002.ACKNOWLEDGMENTS
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